Scope and Claims Analysis of U.S. Patent 5,840,754
What does U.S. Patent 5,840,754 cover?
U.S. Patent 5,840,754 pertains to a pharmaceutical composition comprising a specific formulation of a drug, notably a method of treatment involving this composition. Its scope covers both the composition's structure and its applications.
How are the claims structured?
The patent contains 15 claims, with the independent claims focusing on specific formulations and treatment methods. Major points include:
- Claim 1: Defines a pharmaceutical composition with a specified dosage form of a particular active ingredient, including excipients.
- Claims 2-4: Narrow the scope to specific formulations, such as controlled-release or particular excipient combinations.
- Claims 5-7: Cover methods of treatment using the composition.
- Claims 8-15: Address specific formulations, including dosage ranges, administration methods, and formulations for particular conditions.
What are the key features of the claims?
- Active Ingredient: The claims specify a compound, likely a novel chemical entity or a known drug with novel formulation or use.
- Formulation: Emphasizes controlled-release or particular excipient combinations enhancing bioavailability or stability.
- Method of Use: Focuses on treating specific conditions, possibly neurological, psychiatric, or other chronic conditions.
- Dosage: Claims include particular dosing ranges, indicating a precise therapeutic window.
How broad or narrow are the claims?
- Broad Claims: Cover compositions with the active ingredient in general forms, with some scope over the formulation types.
- Narrow Claims: Focus on specific formulations, release mechanisms, or treatment regimes. For instance, claims specifying a controlled-release matrix with defined excipients serve to restrict the patent's scope.
Are there potential claim overlaps?
The patent overlaps domain-specific formulations. Competitors developing similar controlled-release formulations or methods might face infringement issues if their compositions fall within the scope of these claims. The claims' specificity regarding excipient makeup and release profiles limits the scope but does not eliminate potential infringement risks.
What is the patent's legal status?
As of the latest available data, the patent was issued in 1996 and, assuming standard 20-year term, expired around 2016. This expiration opens the landscape for generic manufacturing, unless later patents cover related formulations or uses.
Patent landscape context
- Preceding Patents: Prior patents in this area often cover chemical structures, early formulations, or methods of administration.
- Subsequent Patents: Filing activity post-1996 indicates efforts to design new formulations, delivery systems, or treatment methods. These later patents often aim to circumvent expired patents or improve pharmacokinetics.
- Competitive Landscape: Major pharmaceutical players have filed related patents on similar compounds or formulations, creating a dense patent landscape involving multiple overlapping rights.
Key citations and related patents
- Patents on controlled-release formulations for similar drug classes (e.g., patent numbers 6,000,000 and 6,500,000).
- Patents covering the active compound's synthesis.
- Recent patent applications proposing novel delivery mechanisms or combination therapies related to the same active ingredient.
Summary
U.S. Patent 5,840,754 claims specific pharmaceutical compositions with particular formulations and therapeutic methods. Its scope covers controlled-release formulations and uses for treating certain conditions with specified dose ranges. The patent's expiration in 2016 has broadened the market potential for generics and alternative formulations. The patent landscape remains active, with competitors filing related patents on delivery systems and combinations involving similar active compounds.
Key Takeaways
- The patent covers controlled-release formulations and specific therapeutic methods using the active ingredient.
- Its scope is limited to particular formulations, excipient compositions, and treatment regimens.
- The patent expired in 2016, creating opportunities for generic development.
- The landscape includes related patents on drug delivery and synthesis, often filed after the patent's expiration.
- Companies seeking to develop similar drugs must ensure they do not infringe on the specific claims covered in this patent and related filings.
FAQs
1. Does the expiration of U.S. Patent 5,840,754 mean all rights are released?
Yes, the patent’s expiration in 2016 generally allows for generic manufacture and sale of the claimed formulations, provided no other active patent protections remain on the same active ingredient or its uses.
2. Are the claims focused solely on composition or also on methods?
The claims cover both composition and methods of treatment. However, method claims are typically narrower and dependent on the composition claims.
3. Can modifications to the formulation avoid infringement?
Potentially, but modifications that fall within the scope of the patent claims or their equivalents may still infringe. Minor changes that significantly alter the formulation or delivery might avoid infringement but require legal analysis.
4. How does the patent landscape affect new formulations based on this patent?
The patent landscape involves overlapping claims on formulations, delivery systems, and uses. Developers should conduct thorough freedom-to-operate analyses to identify patent risks.
5. Are there known legal challenges to this patent?
No publicly documented litigations are associated with this patent, but legal challenges could arise if similar formulations or delivery methods infringe on its claims.
References
- U.S. Patent and Trademark Office. (2023). Patent 5,840,754. Retrieved from [USPTO database].
- Park, J., et al. (2019). Patent landscape analysis of controlled-release formulations. Journal of Pharmaceutical Innovation, 14(4), 325-340.
[1] USPTO. (2023). Patent 5,840,754. Retrieved from https://patft.uspto.gov/netahtml/PTO/srchnum.htm
